Presentations & Publications



  • The role of infection models and PK/PD modelling for optimising care of critically ill
    patients with severe infections.
    Tängdén T, Ramos Martín V, Felton TW, Nielsen E, Marchand S, Brüggemann RJ, Bulitta JB, Bassetti M, Theuretzbacher U, Tsuji BT, Wareham DW, Friberg LE, De Waele JJ, Tam VH, Roberts JA; Infection Section for the European Society of Intensive Care Medicine, the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases, the International Society of Anti-Infective Pharmacology and the Critically Ill Patients Study Group of European Society of Clinical Microbiology and Infectious Diseases. Intensive Care Med. 2017 Jul;43(7):1021-1032. 


Individualised antibiotic dosing for patients who are critically ill: challenges and potential solutions

The Lancet Infectious Diseases, Early Online Publication, 24 April 2014


Jason A Roberts, Mohd H Abdul-Aziz, Jeffrey Lipman, Johan W Mouton, Alexander A Vinks, Timothy W Felton, William W Hope, Andras Farkas, Michael N Neely, Jerome J Schentag, George Drusano, Otto R Frey, Ursula Theuretzbacher, Joseph L Kuti, on behalf of The International Society of Anti-Infective Pharmacology and the Pharmacokinetics and Pharmacodynamics Study Group of the European Society of Clinical Microbiology and Infectious Diseases.

In this Review, we explore the challenges related to patients and pathogens that contribute to inadequate antibiotic dosing and discuss how to implement a process for individualised antibiotic therapy that increases the accuracy of dosing and optimises care for critically ill patients. 

Product information for parenteral colistin varies substantially across Europe

J Antimicrob Chemother. 2014 Mar 14. [Epub ahead of print].

Theuretzbacher U.

This article is summarising the work from EPASG/ESGAP supported by an ESCMID Study Group Research Grant. More details can be found on the EPASG/ESGAP New Life for Old Antibiotics website.


ESCMID PGTW A Statistical Approach to PK/PD Analysis in Practice

Athens, Greece, October 2012

Course material in the ESCMID OLL

ESCMID PGTW Antimicrobial Susceptibility Testing and Surveillance: from Laboratory to Clinic

Jointly organised with the Resistance Surveillance group (ESGARS)
Madrid, Spain, September 2012

Course material in the ESCMID OLL


Publications - Protein Binding

A mini-review and consensus statement by EPASG in collaboration with ISAP concerning in vitro pharmacodynamic testing of protein binding of antibiotics has been accepted by Antimicrobial Agents and Chemotherapy. An online version will be available soon.

EPASG additionally published a book chapter on protein binding: 
Antimicrobial Distribution and Drug-Drug Interaction in Cancer Patients. Ursula Theuretzbacher, Markus Zeitlinger. In: Principles and Practice of Cancer Infectious Diseases. Safdar, Amar (Ed.), 1st Edition, 2011, 549 p. 122 illus., 74 in color. Humana Press, Hardcover, ISBN 978-1-60761-643-6, Series: Current Clinical Oncology.

Project leader: 

Publication - Antibiotics for the future

Conserving antibiotics for the future - New ways to use old and new drugs from a pharmacokinetic and pharmacodynamic perspective

Johan W. Mouton, Paul Ambrose, Rafael Canton, George L. Drusano, Stephan Harbarth, Alasdair MacGowan, Ursula Theuretzbacher and John Turnidge

Drug Resist Updat. 2011 Mar 25. [Epub ahead of print]

As a result of the Uppsala Conference “Global Need for Effective Antibiotics-Moving towards Concerted Action” (see news item below) members of EPASG submitted this publication to the journal “Drug Resistance Updates” in collaboration with ISAP.

EU-US Task force on Antimicrobial Resistance Conference: Global Need for Effective Antibiotics-Moving towards Concerted Action, Uppsala, Sweden, 6 -8 September 2010

This invitational conference recommended concrete solutions to critical issues such as establishing a framework for priority setting for research and development of new drugs and diagnostic methods, enhancing knowledge-sharing for drug discovery, and explore different combinations of incentives to reinvigorate the innovation of new antibacterials. The foremost target groups for the conference were the EU Commission, the EU-US Task force on Antimicrobial Resistance and the WHO.
The Core group “New Ways of Using Old and Coming Antibiotics - Development of Combination Therapies, Dosage and Cycling” was chaired by Johan Mouton and several EPASG members were also involved.
In a meeting in Cologne we produced background documents which served as the basis for the workshop discussions and the later publication of the proceedings of the conference. A publication has been submitted with action recommendations.

Project Leader:

TATFAR – Comment

EPASG comments and suggestions on the consultation programme of TATFAR: Consultation on the Transatlantic Task Force on Antimicrobial Resistance (TATFAR) - Combating Antibiotic Resistance in Transatlantic Cooperation.

Document prepared by: 

EMA – Draft Guideline

Commented on EMA’s draft guideline: Guideline on the Evaluation of Medicinal Products indicated for Treatment of Bacterial Infections

Project leader: